Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001854 | 1.00 | GPR119 (0.37) | GPR119RECQLHSD17B10SETD7HPGD | |
| SCHEMBL16680969 | 1.00 | GPR119 (0.37) | GPR119RECQLHSD17B10SETD7HPGD | |
| SCHEMBL31001845 | 1.00 | GPR119 (0.37) | GPR119RECQLHSD17B10SETD7HPGD | |
| SCHEMBL19628322 | 0.87 | GPR119 (0.35) | GPR119RECQLHSD17B10SETD7HPGD | |
| SCHEMBL17730433 | 0.85 | ATM (0.34) | RECQLHSD17B10HPGDPTPN2PTPN1 | |
| SCHEMBL16701763 | 0.83 | MAPT (0.32) | MAPT | |
| SCHEMBL9939055 | 0.82 | RECQL (0.50) | GPR119RECQLHPGDPTPN2PTPN1 | |
| SCHEMBL2454863 | 0.78 | HSD17B10 (0.47) | HSD17B10HPGDALDH1A1NPC1KMT2A | |
| SCHEMBL2454866 | 0.78 | HSD17B10 (0.47) | HSD17B10HPGDALDH1A1NPC1KMT2A | |
| SCHEMBL1769461 | 0.77 | NR1H2 (0.40) | RECQLHPGDPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| EP-3215505-B1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | Bayer Pharma AG (DE) | 2019-07-24 | — | — | EP | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| EP-3066100-B1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma AG (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | US | disclosed |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-06 | — | — | US | disclosed |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-16 | — | — | US | disclosed |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| US-9598417-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-21 | — | — | US | disclosed |
| EP-3066100-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-14 | — | — | EP | disclosed |
| WO-2016071216-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2015067549-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015067549-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AS INHIBITORS OF FIBRINOLYSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-14 | — | — | WO | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344739-A1 | (AZA)PYRIDOPYRAZOLOPYRIMIDINONES AND INDAZOLOPYRIMIDINONES AND THEIR USE | SERPINB6, SERPINC1, SERPINE1 | GPR119 4274/4885RECQL 245/4885HSD17B10 2949/4885 |
| US-10118930-B2 | Piperidinylpyrazolopyrimidinones and their use | HAMP, SERPINC1, PRSS8 | GPR119 4770/4885RECQL 1094/4885HSD17B10 3305/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | GPR119 4274/4885RECQL 245/4885HSD17B10 2949/4885 |
| US-20170334917-A1 | PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE | HAMP, SERPINC1, PRSS8 | GPR119 4770/4885RECQL 1094/4885HSD17B10 3305/4885 |
| US-20150126449-A1 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | GPR119 4274/4885RECQL 245/4885HSD17B10 2949/4885 |
| US-10098883-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | GPR119 4274/4885RECQL 245/4885HSD17B10 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.